Aviado · Research
Longevity Daily
Thursday, October 15, 2026
Listen
Today's Brief
Aging reversal is today's lead story: a Harvard team identified a single gene, SRSF1, that extended mouse lifespan by 14% and reversed senescence and inflammaging without disrupting cell identity. On the clinical front, a phase 2 RCT published in Nature Metabolism found senolytics cleared liver fibrosis in nearly half of MASH patients — the clearest human evidence yet that clearing senescent cells reverses organ-level aging. This issue also features our Aviado deep-dive on how vitamin A's retinoid pathway independently boosts hemoglobin, plus new genomic evidence from 457,986 UK Biobank participants that chronic poor sleep may actively drive systemic inflammation.
10 stories4 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
PCOS Linked to Elevated Alzheimer's and Dementia Risk in Women
New research examined the relationship between polycystic ovary syndrome (PCOS — now often termed PMOS) and Alzheimer's disease risk, finding a meaningful association between two conditions that affect large numbers of women. The hormonal and metabolic disruptions characteristic of PCOS may prime neurological aging pathways that increase dementia susceptibility decades later. Women diagnosed with PCOS should consider discussing long-term brain health monitoring with their physicians.
Read more →Alzheimer's Prevention May Need to Start Before Birth, Researchers Argue
A STAT News analysis challenges the conventional midlife framing of Alzheimer's prevention, arguing that the window may extend all the way to maternal health and the infant gut microbiome — territory the Davos Alzheimer's Collaborative is now actively staking out. Without health-economics data showing what early intervention saves, the authors warn that microbiome-based prevention tools will stall before reaching clinical adoption. The piece is advocacy as much as hard science, but it signals where serious prevention researchers believe the field must go next.
Read more →Supplements & Compounds
Vitamin A Boosts Hemoglobin Through a Separate Pathway From Iron Intake
Aviado's deep-dive into vitamin A's retinoid pathway explains how retinoic acid — vitamin A's active metabolite — controls iron mobilization proteins and hemoglobin synthesis through nuclear receptor signaling, independently of dietary iron levels. Randomized trials show vitamin A supplementation consistently raises hemoglobin by ~0.69 g/dL, particularly in those with marginal vitamin A status, and the mechanism is biochemically distinct from simply taking more iron. For anyone tracking hemoglobin or ferritin, inadequate vitamin A may be the missing variable even when iron intake looks sufficient on paper.
Read the full Aviado analysis →Neuriva Is One of America's Best-Selling Brain Supplements. The Evidence Doesn't Back It Up.
A Pharmacy Times clinical review of Neuriva — one of the top-selling brain health supplements in the U.S. — finds that evidence for its key ingredients falls well short of the marketing claims. As demand for cognitive supplements surges with an aging population, this review underscores a broader pattern: most brain products on pharmacy shelves remain largely unsubstantiated in rigorous clinical trials. If you're spending money on brain health supplements, this is a useful benchmark before your next order.
Read more →Research & Papers
Harvard Identifies a Single Gene That Reverses Multiple Hallmarks of Aging
George Church's team at Harvard's Wyss Institute screened thousands of genetic candidates and landed on SRSF1 — an RNA splicing factor — as a master regulator of biological aging. Over-expressing SRSF1 in human cells reversed cellular senescence, protein dysregulation, and chronic inflammaging while leaving cell identity intact, solving a key failure mode of earlier reprogramming approaches. When delivered to aged mice via gene therapy, SRSF1 slowed the rate of aging and extended median lifespan by 14%. This remains a mouse study, but the identification of a single geroprotective gene that addresses multiple aging hallmarks without the identity-loss risk of full reprogramming marks a genuine advance in rejuvenation biology.
Read more →Senolytics Cut Liver Fibrosis in 47% of MASH Patients in Phase 2 RCT
A phase 2 RCT published in Nature Metabolism found that the senolytic combination dasatinib + quercetin (D+Q) improved liver fibrosis by at least one stage in 47% of MASH patients, versus just 7% on placebo. Single-nucleus RNA sequencing in the same trial confirmed that senescence- and fibrosis-linked genes were directly downregulated in treated patients — connecting the clinical benefit to the cellular mechanism in a single study. This is one of the strongest human trials yet demonstrating that clearing senescent cells can reverse measurable organ-level aging.
Read more →A Blood Metabolomics Clock Predicts Biological Age and Mortality Risk From Age 1 to 96
A landmark study in Science Translational Medicine profiled plasma metabolomes from 18,476 people spanning ages 1 to 96, identifying 56 age-associated metabolites that together form a "metabolomic age" clock. Participants whose metabolomic age outpaced their chronological age faced significantly higher rates of fatty liver, hypertension, diabetes, and all-cause mortality during six years of follow-up through 2025. The scale and lifespan-wide scope make this one of the most comprehensive biological aging biomarker studies to date, though the cohort is currently China-specific.
Read more →Lifestyle & Nutrition
Bad Sleep May Directly Drive Systemic Inflammation, Large Genomic Study Finds
A genome-wide study of 457,986 UK Biobank participants found that insomnia is genetically associated with elevated C-reactive protein (CRP), a key marker of systemic inflammation — and Mendelian randomization analysis indicates insomnia liability drives CRP elevation rather than the reverse. The analysis identified 125 shared genetic loci between insomnia and CRP, with pathways implicating cellular senescence and immune signaling. For longevity-focused readers, this adds genetic-level support to the case that chronic poor sleep actively fuels the low-grade inflammation that accelerates biological aging.
Read more →Industry & Policy
Loyal Becomes First Company With Two Dog Longevity Drugs Accepted by the FDA
Loyal, the biotech focused on extending healthy lifespan in dogs, has secured a second Reasonable Expectation of Effectiveness (RXE) acceptance from the FDA for a canine longevity drug — a regulatory first. While the drug is designed for dogs, Loyal's progress is closely tracked by the broader longevity field: the company is demonstrating that aging can be treated as a disease target within the existing FDA framework. For human longevity medicine, this is a proof of regulatory concept worth following closely.
Read more →FDA Supplement Listing Requirement Would Boost Consumer Trust, CRN Survey Finds
A new Council for Responsible Nutrition (CRN) survey finds consumers express significantly higher confidence in supplement brands registered on an FDA product listing database. The proposed rule would require manufacturers to submit product names, ingredient lists, label copies, allergen statements, and health claims — creating a public record that doesn't currently exist for the supplement market. For longevity supplement consumers, mandatory listing could make it meaningfully easier to verify what's actually in the products you take.
Read more →